Herbs and Other Botanicals in Cancer Patient Care

被引:21
作者
Cassileth, Barrie [1 ]
Yeung, K. Simon [1 ]
Gubili, Jyothirmai [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Integrat Med Serv, New York, NY 10021 USA
关键词
D O I
10.1007/s11864-008-0061-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Non-prescription herbal remedies are commonly used by cancer patients in efforts to control their disease or to manage symptoms associated with cancer and cancer treatments. We address the issues surrounding the use of herbs, herbal compounds, and other botanical agents in the oncology context. Botanicals are biologically active agents that can be useful under appropriate circumstances, but they may be counterproductive when used by patients on chemotherapy or on other prescription medications. Herbs and other botanical agents, despite common public belief, are not benign. They should be understood as unrefined pharmaceuticals, with the capacity to produce physiologic change for better or worse. Indeed, many prescription drugs, chemotherapeutic agents among them, were derived from plants and other natural agents, and the search for additional constituents of plants, animals, and minerals for use as pharmaceutical agents remains an active effort on many fronts. Cautions, appropriate application, and potential utility of botanical agents are discussed below, and sources of reliable information are provided.
引用
收藏
页码:109 / 116
页数:8
相关论文
共 51 条
[1]
Barnes Patricia M, 2004, Adv Data, P1
[2]
Bayne CW, 1999, PROSTATE, V40, P232, DOI 10.1002/(SICI)1097-0045(19990901)40:4<232::AID-PROS4>3.0.CO
[3]
2-0
[4]
Saw palmetto for benign prostatic hyperplasia [J].
Bent, S ;
Kane, C ;
Shinohara, K ;
Neuhaus, J ;
Hudes, ES ;
Goldberg, H ;
Avins, AL .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :557-566
[5]
Bertram JS, 1999, NUTR REV, V57, P182, DOI 10.1111/j.1753-4887.1999.tb06941.x
[6]
Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia [J].
Boyle, P ;
Robertson, C ;
Lowe, F ;
Roehrborn, C .
UROLOGY, 2000, 55 (04) :533-539
[7]
*CDER, GUID IND BOT DRUG PR
[8]
CHU DT, 1988, J CLIN LAB IMMUNOL, V25, P119
[9]
CHU DT, 1988, J CLIN LAB IMMUNOL, V25, P125
[10]
Correa-Velez Ignacio, 2005, J Palliat Med, V8, P953, DOI 10.1089/jpm.2005.8.953